Exponential Health, an innovative concierge medicine practice in
Michigan, adopts Cardio Diagnostics' AI-driven epigenetic-genetic
tests, marking a new era in personalized and preventive cardiac
care.
In a significant stride towards transforming cardiovascular
healthcare in concierge specialty and primary care offices,
Exponential Health, an innovative concierge medical practice led by
Dr. William Baer, is set to offer Cardio Diagnostics Holdings,
Inc.’s (Nasdaq: CDIO) clinical epigenetic-genetic cardiovascular
tests, Epi+Gen CHD and PrecisionCHD, to their patients. As a
result, Exponential Health is expanding access to a new chapter in
the proactive management of heart disease.
Exponential Health emphasizes a more personalized and
patient-centric approach to preventive care. Its value-based care
model allows Exponential Health to dedicate more time to each
patient, conducting comprehensive assessments and creating tailored
preventive care plans for them.
A Synergy of Innovation and Expertise in Precision
Care
The U.S. concierge medicine market size was estimated to be at
USD 6.7 billion in 2023 and is projected to grow at a compound
annual growth rate (CAGR) of 10.37% from 2024 to 2030, reaching USD
13.3 billion. This growth is driven by increasing demand for
convenient care, advantages offered by concierge medicine to
patients, and higher career satisfaction among concierge
physicians.
Concierge practices such as Exponential Health are leading the
way in adopting epigenetic cardiovascular solutions. This
partnership combines advanced medical technologies with
unparalleled and personalized clinical expertise, setting a new
benchmark for concierge practices enhancing preventive cardiology
in primary care. Exponential Health aims to proactively identify
and monitor patients using Cardio Diagnostics’ solutions to
intervene with an innovative framework for early assessment,
diagnosis, and management of coronary heart disease, which is the
most common type of heart disease and the primary cause of heart
attacks. The practice offers patients a more personalized
healthcare journey.
Dr. William Baer, Founder of Exponential Health, expressed
enthusiasm about the collaboration, stating, "Our alliance with
Cardio Diagnostics is a testament to our dedication to embracing
innovative solutions that enhance patient care. Their advanced
cardiovascular tests will empower us to detect and address heart
disease with unprecedented precision, aligning perfectly with our
mission to deliver superior, individualized care."
Cardio Diagnostics' cutting-edge tests, Epi+Gen CHD and
PrecisionCHD, are designed to assess the risk of coronary heart
disease events and aid in diagnosing coronary heart disease,
respectively, using a blend of genomics, epigenomics, and
artificial intelligence. These tests coupled to Cardio Diagnostics’
Actionable Clinical Intelligence platform can provide critical
insights into a patient's cardiovascular health at the molecular
level, enabling earlier intervention and tailored treatment
strategies with higher precision.
Transforming Cardiovascular Health Management
"We are thrilled to partner with Dr. Baer and Exponential
Health," said Meesha Dogan, Ph.D., CEO and Co-Founder of Cardio
Diagnostics. "This partnership is a powerful demonstration of our
shared commitment to advancing cardiovascular health through
innovation. By integrating our precision medicine solutions into
Exponential Health’s practice, we are poised to make a significant
impact on preventing heart disease and improving outcomes for
patients."
This collaboration arrives at a pivotal moment, as
cardiovascular disease remains the leading cause of death globally.
Integrating Cardio Diagnostics' advanced tests into Exponential
Health's offerings is a proactive step toward mitigating this
global health challenge. It will provide patients with access to
state-of-the-art diagnostic tools that facilitate informed
decision-making and personalized prevention plans.
About Cardio Diagnostics
Cardio Diagnostics is an artificial intelligence-powered
precision cardiovascular medicine company that makes cardiovascular
disease prevention, detection, and management more accessible,
personalized, and precise. The Company was formed to further
develop and commercialize clinical tests by leveraging a
proprietary Artificial Intelligence (AI)-driven Integrated
Genetic-Epigenetic Engine ("Core Technology") for cardiovascular
disease to become one of the leading medical technology companies
for improving prevention, detection, and treatment of
cardiovascular disease. For more information, please visit
www.cardiodiagnosticsinc.com.
About Exponential Health
Exponential Health is a leading concierge medical practice that
prioritizes preventive medicine and early detection to optimize
health and wellness. Founded by Dr. William Baer, a pioneer in
preventive and personalized medicine, Exponential Health leverages
cutting-edge technology and customized care to revolutionize the
healthcare experience and empower patients to achieve their best
health outcomes.
Forward-Looking Statements
Certain statements and information included in this press
release constitute "forward-looking statements" within the meaning
of the Private Securities Litigation Act 1995. When used in this
press release, the words or phrases "will," "will likely result,"
"expected to," "will continue," "anticipated," "estimate,"
"projected," "intend," "goal," or similar expressions are intended
to identify "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Such statements
are subject to certain risks, known and unknown, and uncertainties,
many of which are beyond the control of the Company. Such
uncertainties and risks include but are not limited to, our ability
to successfully execute our growth strategy, changes in laws or
regulations, economic conditions, dependence on management,
dilution to stockholders, lack of capital, the effects of rapid
growth upon the Company and the ability of management to
effectively respond to the growth and demand for products and
services of the Company, newly developing technologies, the
Company's ability to compete, regulatory matters, protection of
technology, the effects of competition and the ability of the
Company to obtain future financing. An extensive list of factors
that can affect future results are discussed in the Current Report
on Form 10-K for the period ended December 31, 2022, and Forms 10-Q
for the period ended March 31, 2023, and September 30, 2023, under
the heading "Risk Factors" in Part I, Item IA thereof, and other
documents filed from time to time with the Securities and Exchange
Commission. Such factors could materially adversely affect the
Company's financial performance and could cause the Company's
actual results for future periods to differ materially from any
opinions or statements expressed within this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240409605762/en/
Investors: Gene Mannheimer Investor Relations
855-226-9991 investors@cardiodiagnosticsinc.com
Media & Public Relations: Khullani Abdullahi
855-226-9991 pr@cardiodiagnosticsinc.com
Cardio Diagnostics (NASDAQ:CDIO)
過去 株価チャート
から 10 2024 まで 11 2024
Cardio Diagnostics (NASDAQ:CDIO)
過去 株価チャート
から 11 2023 まで 11 2024
